MX371090B - Composicion farmaceutica que contiene derivado de hidantoina. - Google Patents
Composicion farmaceutica que contiene derivado de hidantoina.Info
- Publication number
- MX371090B MX371090B MX2016013684A MX2016013684A MX371090B MX 371090 B MX371090 B MX 371090B MX 2016013684 A MX2016013684 A MX 2016013684A MX 2016013684 A MX2016013684 A MX 2016013684A MX 371090 B MX371090 B MX 371090B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- containing pharmaceutical
- hydantoin derivative
- formula
- hydantoin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001469 hydantoins Chemical class 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000000845 cartilage Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2014/065262 WO2015189901A1 (ja) | 2014-06-09 | 2014-06-09 | ヒダントイン誘導体含有医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016013684A MX2016013684A (es) | 2017-01-20 |
| MX371090B true MX371090B (es) | 2020-01-16 |
Family
ID=54833033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016013684A MX371090B (es) | 2014-06-09 | 2014-06-09 | Composicion farmaceutica que contiene derivado de hidantoina. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9993462B2 (enExample) |
| EP (1) | EP3153166B1 (enExample) |
| KR (2) | KR102266021B1 (enExample) |
| CN (2) | CN106572994B (enExample) |
| AU (1) | AU2014397042B2 (enExample) |
| BR (1) | BR112016003511B8 (enExample) |
| CA (1) | CA2949023C (enExample) |
| MX (1) | MX371090B (enExample) |
| RU (1) | RU2701168C2 (enExample) |
| WO (2) | WO2015189901A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ707946A (en) * | 2012-12-10 | 2019-11-29 | Chugai Pharmaceutical Co Ltd | Hydantoin derivative |
| US20210290541A1 (en) * | 2018-07-30 | 2021-09-23 | Chugai Seiyaku Kabushiki Kaisha | Solid dispersion of hydantoin derivative |
| CN120418354A (zh) | 2022-12-28 | 2025-08-01 | 中外制药株式会社 | 含有待分散的物质的固体分散体、含有其的药物组合物及其生产方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1135470A (ja) | 1997-07-23 | 1999-02-09 | Teijin Ltd | ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤 |
| ATE305003T1 (de) | 1998-12-11 | 2005-10-15 | Hoffmann La Roche | Zyklische hydrazinderivate als tnf-alpha inhibitoren |
| WO2002017911A1 (en) | 2000-08-30 | 2002-03-07 | Teijin Limited | Parathyroid hormone production inhibitors containing vitamin d3 derivatives |
| AP2001002318A0 (en) | 2000-10-26 | 2001-12-31 | Pfizer Prod Inc | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
| EP1713782A4 (en) | 2004-02-11 | 2009-11-11 | Smithkline Beecham Corp | PTH AGONISTS |
| EP1713815A4 (en) | 2004-02-11 | 2009-03-11 | Smithkline Beecham Corp | PTH AGONISTS |
| CA2582593A1 (en) * | 2004-10-07 | 2006-04-20 | Merck & Co., Inc. | Cgrp receptor antagonists |
| WO2007135417A1 (en) | 2006-05-19 | 2007-11-29 | James Black Foundation | Benzotriazepinone derivatives |
| WO2007149873A2 (en) * | 2006-06-20 | 2007-12-27 | Wyeth | Kv1.5 potassium channel inhibitors |
| TW200831080A (en) * | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| DE602008003221D1 (de) * | 2007-06-07 | 2010-12-09 | Hoffmann La Roche | Prolinamidderivate als nk3-antagonisten |
| EA017919B1 (ru) | 2007-12-10 | 2013-04-30 | Новартис Аг | Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| US8513193B2 (en) | 2008-10-13 | 2013-08-20 | University Of Rochester | Protecting and repairing cartilage and musculoskeletal soft tissues |
| JP5671453B2 (ja) * | 2009-04-28 | 2015-02-18 | 中外製薬株式会社 | スピロイミダゾロン誘導体 |
| NZ707946A (en) * | 2012-12-10 | 2019-11-29 | Chugai Pharmaceutical Co Ltd | Hydantoin derivative |
-
2014
- 2014-06-09 RU RU2016113896A patent/RU2701168C2/ru active
- 2014-06-09 US US15/317,221 patent/US9993462B2/en active Active
- 2014-06-09 KR KR1020167030563A patent/KR102266021B1/ko active Active
- 2014-06-09 CA CA2949023A patent/CA2949023C/en active Active
- 2014-06-09 EP EP14894764.1A patent/EP3153166B1/en active Active
- 2014-06-09 BR BR112016003511A patent/BR112016003511B8/pt active Search and Examination
- 2014-06-09 MX MX2016013684A patent/MX371090B/es active IP Right Grant
- 2014-06-09 CN CN201480079652.7A patent/CN106572994B/zh active Active
- 2014-06-09 WO PCT/JP2014/065262 patent/WO2015189901A1/ja not_active Ceased
- 2014-06-09 AU AU2014397042A patent/AU2014397042B2/en not_active Ceased
-
2015
- 2015-06-09 KR KR1020177000115A patent/KR102382331B1/ko active Active
- 2015-06-09 CN CN201580039807.9A patent/CN106535892B/zh active Active
- 2015-06-09 WO PCT/JP2015/066543 patent/WO2015190451A1/ja not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016113896A3 (enExample) | 2018-07-18 |
| MX2016013684A (es) | 2017-01-20 |
| CN106535892B (zh) | 2020-09-18 |
| EP3153166A4 (en) | 2018-01-17 |
| AU2014397042A1 (en) | 2016-02-11 |
| KR20170010439A (ko) | 2017-01-31 |
| KR102266021B1 (ko) | 2021-06-16 |
| BR112016003511A8 (pt) | 2018-01-30 |
| CA2949023C (en) | 2021-10-12 |
| EP3153166A1 (en) | 2017-04-12 |
| WO2015190451A1 (ja) | 2015-12-17 |
| EP3153166B1 (en) | 2022-08-03 |
| US9993462B2 (en) | 2018-06-12 |
| KR102382331B1 (ko) | 2022-04-01 |
| CN106572994A (zh) | 2017-04-19 |
| BR112016003511A2 (enExample) | 2017-08-01 |
| WO2015189901A1 (ja) | 2015-12-17 |
| CA2949023A1 (en) | 2015-12-17 |
| CN106572994B (zh) | 2020-09-18 |
| RU2701168C2 (ru) | 2019-09-25 |
| AU2014397042B2 (en) | 2020-04-09 |
| US20170112812A1 (en) | 2017-04-27 |
| BR112016003511B1 (pt) | 2022-11-08 |
| KR20170010354A (ko) | 2017-01-31 |
| RU2016113896A (ru) | 2018-07-18 |
| BR112016003511B8 (pt) | 2023-10-03 |
| CN106535892A (zh) | 2017-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021001091A (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington. | |
| PH12016501813A1 (en) | 1,3-benzodioxole derivative | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| MX2016016593A (es) | Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos. | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12017501539A1 (en) | Disacetoxytubulysin h and analogs thereof | |
| EA201790627A1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| MX383577B (es) | Derivados sustituidos de guanidina. | |
| GEP201706760B (en) | Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same | |
| MY162886A (en) | Novel tetrahydropyridopyrimidine compound or salt thereof | |
| PH12017501280A1 (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
| MX2020006436A (es) | Compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| MX2020006434A (es) | Nuevos compuestos inhibidores del blanco mecanistico de rapamicina (mtor). | |
| GEP20186893B (en) | Pyrazines modulators of gpr6 | |
| PH12016500461A1 (en) | Polyethylene glycol-containing composition | |
| MX2017009292A (es) | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3. | |
| PH12015501146A1 (en) | Hydantoin derivative | |
| MX2016013684A (es) | Composicion farmaceutica que contiene derivado de hidantoina. | |
| MA39877A (fr) | Formes solides d'un composé pharmaceutiquement actif | |
| MX387920B (es) | Peptidos antagonistas de prgc. | |
| EA201690908A1 (ru) | Пиразолопиримидиновые соединения | |
| PH12017501134A1 (en) | Fumagillol derivatives | |
| MX2019007786A (es) | Compuestos sustituidos de guanidina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |